Dr. Gaurav Shah MD
Professor of Ophthalmology, WASHINGTON UNIVERSITY MEDICAL CENTER
Member of the Healthcare Council
Council Member Biography
Gaurav Shah, MD, is Professor of Ophthalmology at the Washington University Medical Center in Missouri. Dr. Shah is a national expert in the care of patients with diabetic retinopathy/diabetic macular edema, age-related macular degeneration, and retinal detachments, as well as the economics of retinal healthcare. He has been involved in the pivotal trials and publications regarding Macugen, Lucentis, and PDT and is working on new combinations of PDT and Avastin. Dr. Shah has presented at many national and international meetings and has published over four book chapters and approximately 100 peer-reviewed articles. He is an elected member of the Retina Society, the Macula Society, and the American Academy of Ophthalmology. Dr. Shah is also involved in 15 phase 2 and phase 3 clinical trials dealing with ARMD and diabetic macular edema, dry macular degeneration, and new drug delivery devices. He is Editor and Chief of the Retina Times (official publication of the ASRS (American Society of Retina Specialists.) (This is me - Update Profile)
Employment History
- 1999 - Unspecified
- Professor of Ophthalmology, WASHINGTON UNIVERSITY MEDICAL CENTER
GLG NewsSM Analyses by Gaurav Shah
GLG News is now G+ Insights
-
G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.
-
JSM 6427: the new face of armd therapy
July 30, 2007
FDA Accepts Jerini Ophthalmic's IND of JSM 6427 for the Treatment of AMD | www.pipelinereview.com
1. A molecule that allows on to stop neovascular armd to form from dry armd 2. A product with a potentially large market share compared to the current agents available 3. A compound that could have a sustained drug delivery module
-
PDT still a viable alternatvie
March 14, 2007
PDT more effective for myopic CNV in patients 55 years and younger, study finds | www.osnsupersite.com
PDT remains a viable option for patients with new blood vessels from high myopia. Despite the era of antivegf therapy PDT may be safer in these patients than repeated injection. This article yet again defies another area for the use of PDT. PDT will be continued to be complemented to the currently available therapies of antivegf for not only myopic degeneration, but also macular degeneration.
-
November 20, 2006
Laser Treatment Ineffective In Preventing Vision Loss In Early Age-Related Macular Degeneration | www.pharma-lexicon.com
It is not surprising that laser therapy is not effective for patients with macular degeneration. Initially there was a significant interest in this therapy, but as this well designed trial has shown us that thermal treatment is not the answer for dry ARMD. AREDS I and AREDS II are now the most important vitamin related studies with ARMD. The future for dry ARMD lies potentially with encapsulated compounds that may be delivered to the back of the eye for geographic atrophy. Currently the Anti-VEGF agents Lucentis and Avastin are the gold standard for wet ARMD. PDT in combination with these agents may be useful for decreasing the number in the injections involved.
GLG Study Groups with Gaurav Shah(?)
| Study Group Name | No. Members |
|---|---|
| Ophthalmologists | 1707 |
| Ophthalmologists (US) | 1196 |
| Physicians who Implant Intraocular Lenses | 248 |
| Ophthalmologists who Treat Macular Degeneration (US) | 215 |
| LASIK Surgeons | 196 |
GLG Live Meetings with Gaurav Shah(?)
Gaurav Shah has not participated in any GLG Live Meetings.
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.